4D Molecular Therapeutics, Inc. (FDMT) — Dilution Risk Analysis
Current Snapshot
4D Molecular Therapeutics, Inc. (FDMT) has a DilutionWatch score of 30/10 and is classified as MEDIUM risk. The score date in the source data is 2026-09-29T03:44:34.753246.
This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.
Dilution Risk Score
Score: 30/10 Source (as of 2026-09-29T03:44:34.753246)
Recent SEC Filings
Recent filing forms in the source payload: XBRL 2.
| Form | Filed | Accession |
|---|---|---|
| xbrl | 2025-12-31 | xbrl-3897-xbrl_warrant |
| xbrl | 2020-12-31 | xbrl-3897-xbrl_convertible |
Dilution Risk Drivers
| Driver | Stored Value | Source |
|---|---|---|
| Cash runway | 25 months | Source |
| Three-year share count growth | 16.43% | Source |
DilutionWatch Analysis
- Risk Level
- MEDIUM (Score: 30/10) Source
- Cash Runway
- 25 months Source
- Share Count Growth (3-Year)
- 16.43% Source
What This Page Does Not Estimate
DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.
Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.